health Alto Neuroscience Raises $120M to Advance ALTO-207 for Treatment-Resistant Depression
Alto Neuroscience secures $120M financing led by Commodore Capital to fund Phase 2b/3 trials of ALTO-207, a pramipexole-ondansetron combo for treatment-resistant depression.
